RAYOS Drug Patent Profile
✉ Email this page to a colleague
When do Rayos patents expire, and what generic alternatives are available?
Rayos is a drug marketed by Horizon and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-three patent family members in twenty-nine countries.
The generic ingredient in RAYOS is prednisone. There are sixteen drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the prednisone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rayos
A generic version of RAYOS was approved as prednisone by WATSON LABS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RAYOS?
- What are the global sales for RAYOS?
- What is Average Wholesale Price for RAYOS?
Summary for RAYOS
| International Patents: | 53 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Patent Applications: | 4,343 |
| Drug Prices: | Drug price information for RAYOS |
| What excipients (inactive ingredients) are in RAYOS? | RAYOS excipients list |
| DailyMed Link: | RAYOS at DailyMed |
Pharmacology for RAYOS
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for RAYOS
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RAYOS | Delayed-release Tablets | prednisone | 5 mg | 202020 | 1 | 2012-11-26 |
US Patents and Regulatory Information for RAYOS
RAYOS is protected by seven US patents.
Patents protecting RAYOS
Delayed release tablet with defined core geometry
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY,GASTROINTESTINAL,DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
Delayed release tablet with defined core geometry
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
Delayed release tablet with defined core geometry
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Delayed release tablet with defined core geometry
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
Delayed release tablet with defined core geometry
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
Delayed release tablet with defined core geometry
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
Delayed-release glucocorticoid treatment of rheumatoid disease
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RAYOS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RAYOS
See the table below for patents covering RAYOS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008015018 | ⤷ Sign Up | |
| Singapore | 10201503411Q | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE | ⤷ Sign Up |
| Brazil | PI0717052 | TRATAMENTO DE DOENÇA REUMATOIDE COM GLUCOCORTICOIDE DE LIBERAÇÃO RETARDADA | ⤷ Sign Up |
| South Africa | 200106739 | Corticosteroid formulation. | ⤷ Sign Up |
| Austria | 512659 | ⤷ Sign Up | |
| Canada | 2523158 | COMPRIME A ACTION RETARDEE ET A GEOMETRIE DE NOYAU DEFINIE (DELAYED RELEASE TABLET WITH DEFINED CORE GEOMETRY) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
